…blasts stimulated with rh- TGFβ (n=10) using the NMII inhibitor blebbistatin, the pan-ROCK inhibitor Y-27632, and the ROCK2-selective inhibi…
All extracted drugs
Showing 1,201–1,260 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Articles mentioning drugs
10,506 articles · page 111 of 876…nalysis of HUVEC and HMDECs treated with Shh, TGFβ or TGFβ plus Glabrescione B for 5 days showed 408 DEGs shared by TGFβ and Shh. Reactome enr…
…analyze long term outcome of patients with SSc-ILD treated with tocilizumab (TCZ), rituximab (RTX), and abatacept (ABA) which became availa…
P.211 Ruxolitinib therapy in pansclerotic morphea refractory to autologous stem-cell transplantation
… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…
…SSc will be randomized 2:1 to receive weekly administrations of efgartigimod or placebo PH20 SC (coformulated with recombinant human hyaluro…
…SF-36).Conclusions These findings suggest that long-term use of rituximab provides sustained clinical benefit in patients with progressiv…
…slowing lung function decline in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more eff…
… are limited. Our study aimed to evaluate changes in PM-Scl100, PM-Scl75, and anti-Ku antibody positivity before and during the pandemic…
…; P=0.012 for stroke etiology×tirofiban interaction).Conclusion Tirofiban may be associated with favorable outcomes in non-AS BAO without…
…ty over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease acti…
…ombinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16 µg/kg: Cohort A1 and B1 and 24…